

Neuronal and glial markers in tumours of neuroblastic origin

F. Carlei¹, J.M. Polak¹, A. Ceccamea⁵, P.J. Marangos³, D. Dahl²,
D. Cocchia⁴, F. Michetti⁴, E. Lezoché⁶, and V. Speranza⁶

¹ Department of Histochemistry, Royal Postgraduate Medical School, Hammersmith Hospital, London W12 OHS, Great Britain

² Dept. of Neuropathology, Harvard Medical School, Boston, MA, USA

³ Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, MD 20205, USA

⁴ Department of Anatomy, Università Cattolica, Rome

⁵ 2nd Department of Pathology, Università la Sapienza, Rome, Italy

⁶ 6th Surgical Clinic, Università la Sapienza, Rome, Italy

Summary. The presence and distribution of different neural markers in 30 neuroblastic tumours (neuroblastomas, ganglioneuroblastomas) and 6 non-neuroblastic tumours were investigated by immunocytochemistry. Neuron-specific enolase (NSE), S-100 protein, tyrosine hydroxylase, neurofilaments and glial fibrillary acidic protein (GFAP) were localised in 3 undifferentiated neuroblastic tumours (group A), 12 poorly differentiated tumours (group B) and 15 well differentiated neuroblastic tumours (group C). Non-neuroblastic tumours (3 lymphomas and 3 Ewing sarcomas) showed no immunoreactivity.

Tyrosine hydroxylase and, in particular, NSE were found in mature ganglion cells and developing neuroblasts of poorly and well differentiated tumours (groups B and C). S-100 was localised in neuroblasts with slender cytoplasmic processes in the same groups. Neurofilaments were detected in ganglion cells and differentiated neuroblasts (groups B and C) while GFAP was localised in immature neuroblasts of undifferentiated and poorly differentiated tumours (groups A and B). Thus, there are differences in the neural proteins found in neuroblastic tumours and a wide panel of antibodies against neural markers may be a useful tool in the histological assessment of nervous system neoplasms.

Key words: Cytoskeleton components – Immunocytochemistry – Neuroblastomas – NSE – S-100 – Tyrosine hydroxylase

Neuroblastomas and their differentiated counterparts, ganglioneuroblastomas, are tumours frequently found in infancy.

The histological diagnosis of neuroblastomas is sometimes difficult since their clinical and microscopical characteristics are extremely similar to those presented by other neoplasms such as undifferentiated sarcomas and lymphomas. Neuroblastomas may display different degrees of maturation (Makinen 1972) from undifferentiated through increasing differentiation to benign ganglioneuromas (Cushing and Wohlbach 1927; Fox et al. 1959). Signs of maturation are considered by various authors (Hughes et al. 1974; Ceccamea et al. 1981) to consist of enlarged vesicular nuclei, prominent nucleoli and an increase in the amount of cytoplasm with formation of cytoplasmic processes. The degree of tumour maturation is closely related to prognosis and survival, and an effective evaluation is thus necessary (Hughes et al. 1974).

Various proteins have been extracted from nervous tissue; some of them appear during maturation. They are often restricted to a single cell population (Bradshaw and Schneider 1980) and although some are components of the cytoskeleton, others are known to be involved in specific metabolic processes. These neural proteins include neuron-specific enolase, S-100, the enzyme tyrosine hydroxylase and two types of intermediate filaments forming part of the cytoskeleton – neurofilaments and glial fibrillary acidic protein.

Neuron-specific enolase, a $\gamma\gamma$ dimer of the glycolytic enzyme enolase, is present in neurons of the central and peripheral nervous systems (Marangos et al. 1978) as well as in paraneurons or APUD cells (Pearse 1968; Polak and Bloom 1979) throughout the entire body (Marangos et al. 1982). S-100 protein, a highly acidic water-soluble protein, first detected in astrocytes and Schwann cells (Moore 1965), has also been identified in the peripheral nervous system (Ferri et al. 1982). Tyrosine hydroxylase is localised in all sympathetic structures and can therefore be considered as a marker for this system (Thibault et al. 1981).

During the past few years the different components of the cytoskeleton have been characterised. Neurofilaments (Huneeus and Davison 1970), being about 10 nm in diameter, belong to the group known as intermediate filaments, since their diameter lies between those of the other two major cytoskeletal components, microfilaments (5 nm) and microtubules (about 25 nm). Neurofilaments are specifically restricted to neuronal cells in the central nervous system and in the periphery. On the other hand, astrocytes and glial cells of the central nervous system and peripheral ganglia, exhibit a different cytoskeletal intermediate filament, glial fibrillary acidic protein (GFAP) (Bignami et al. 1972; Jessen and Mirsky 1980).

Several attempts have been made to localize these substances in neoplastic tissues including neuroblastic tumours. NSE immunoreactivity has been localised in ganglioneuroblastomas (Tapia et al. 1981) and elevated levels of NSE have been found in the plasma of children with metastatic neuroblastoma (Zelter et al. 1983). The presence of S-100 has also been identified in neuroblastomas and ganglioneuroblastomas (Kahn et al. 1982; Nakajima et al. 1982). Osborn and Weber (1983) suggested that at least some neuroblastomas are characterised by the presence of neurofilaments.

We have therefore carried out a comparative and systematic search for

the presence of a variety of neural proteins in 30 tumours of neuroblastic origin and 6 of non-neuroblastic origin. Immunocytochemistry was undertaken using a panel of antibodies recognising the following neural antigens: neuron specific enolase, S-100, tyrosine hydroxylase, neurofilaments and GFAP. The purpose was to verify the existence and localization of these markers and their distribution pattern in relation to the degree of maturation of the tumours.

Materials and methods

All the material consisted of large surgical specimens collected during operations performed in the Policlinico Umberto I, Rome, from 1975 to 1980.

The series comprised 30 neuroblastic tumours, 3 small cell lymphomas and 3 Ewing sarcomas.

Table 1A

Antiserum to	Natural antigen	Optimal dilution
Neuron specific enolase (NSE) (Marangos et al. 1978)	Human	1/2000
S-100 protein (Cocchia and Michetti 1981)	Bovine	1/4000
Glial fibrillary acidic protein (GFAP) (Dahl and Bignami 1976)	Human	1/1000
Tyrosine hydroxylase (TH) (Thibault et al. 1981)	Feline (cat)	1/800
Neurofilament protein (68°, 150°, 200° K) (Dahl and Bignami 1977)	Avian (chicken)	1/500

Table 1B. Absorption controls

Antisera to	Antigen				
	NSE	S-100	GFAP	TH	NF
NSE	— (1)	+	+	+	+
S-100	+	— (1)	+	+	+
GFAP	+	+	— (1)		+
TH	+	+	+	— (0.5)	+
NF	+	+	+	+	— (1)

The minimum concentration (nmol/ml diluted antiserum) of antigen required to successfully quench immunostaining is shown in parentheses. (— = negative staining; + = positive staining) Cross-absorption controls were carried out using up to 10 nmol of antigen per ml of diluted antiserum

Table 2A.

Case	Sex	Age (months)	Location	Signs of matura- tion	Detectable markers				
					NF	NSE	S-100	GFAP	TH
<i>Group A (undifferentiated)</i>									
1	M	29	Neck	0	—	—	—	—	—
2	M	24	Adrenal	0	—	—	—	+	—
3	F	7	Adrenal	0	—	—	—	—	—
<i>Group B (partly differentiated)</i>									
4	F	34	Adrenal	1	+	—	+	—	—
5	F	0	Adrenal	1	+	—	+	—	—
6	M	36	Adrenal	1	—	—	+	+	—
7	F	22	Adrenal	1	—	+	+	—	—
8	M	19	Adrenal	2	+	+	+	—	+
9	M	31	Adrenal	2	—	+	+	—	—
10	F	20	Adrenal	2	—	+	+	+	—
11	M	25	Adrenal	2	+	+	+	—	—
12	F	37	Adrenal	3	+	—	+	—	—
13	F	25	Paraortic	3	+	+	+	—	+
14	M	24	Adrenal	3	+	+	—	—	+
15	M	27	Adrenal	3	+	+	+	—	+
16	F	34	Adrenal	3	—	+	+	—	+
17	M	29	Adrenal	3	+	—	+	—	+
<i>Group C (well differentiated)</i>									
18	M	29	Mediastinum	4	+	+	+	—	—
19	F	11	Adrenal	4	+	+	—	—	+
20	F	22	Adrenal	4	+	+	+	—	+
21	M	25	Adrenal	4	+	+	—	—	+
22	M	20	Adrenal	4	+	—	+	—	—
23	F	26	Adrenal	4	+	+	—	—	+
24	F	29	Adrenal	4	—	+	+	—	—
25	F	29	Adrenal	5	+	+	—	—	+
26	F	8	Adrenal	5	+	+	—	—	+
27	M	34	Adrenal	5	+	+	—	—	+
28	M	29	Neck	5	+	+	+	—	+
29	F	34	Adrenal	5	+	+	—	—	+
30	F	35	Adrenal	5	+	+	+	—	+

Table 2B

Case	Sex	Age (years)	Primary location	Histology	Detectable markers
31	F	4	Left kidney	Lymphoblastic lymphoma	None (within tumour cells)
32	F	3	Paraortic	Lymphoblastic lymphoma	None (within tumour cells)
33	M	3	Pelvic	Lymphoblastic lymphoma	None (within tumour cells)
34	F	5	Femur	Ewing sarcoma	None (within tumour cells)
35	F	10	Knee joint	Ewing sarcoma	None (within tumour cells)
36	M	13	Femur	Ewing sarcoma	None (within tumour cells)

The ages of patients with neuroblastic tumours (14 male, 16 female) varied from 0 to 4 years (2.1 mean) (Table 2A), while patients with non-neuroblastic tumours (2 male, 4 female) ranged from 3 to 13 years (6.3 years mean) (Table 2B).

The tissues were identically fixed in aqueous 10% formalin for 24 h, dehydrated and embedded in paraffin (56° M.P.). Five µm serial sections were mounted on slides pre-coated with poly-L-lysine (Huang et al. 1983). Haematoxylin-eosin staining was carried out for histological examination.

Tumour typing

Various criteria, previously established by others (Makinen 1972) were adopted in order to assess the degree of differentiation among our cases.

The following parameters were considered: 1) presence of large vesicular nuclei 2) development of abundant cytoplasm 3) formation of cytoplasmic processes 4) rosette-like formation of neuroblasts 5) presence of ganglion cells. Depending on the presence of one or more of these our cases were divided into: group A) no parameters of differentiation (undifferentiated), group B) one to three parameters of differentiation (poorly differentiated), group C) four or five parameters of differentiation (well differentiated).

Since our attention was focused on the degree of maturation of tumour cells, other parameters such as lymphocytic infiltration, calcification, extent of necrosis, etc., were not considered, although they may represent important factors with clinical and prognostic implications (Ceccamea et al. 1981).

Immunocytochemistry

The peroxidase anti-peroxidase technique (Sternberger 1979) was applied as follows: The sections were brought to water through xylene and graded alcohols. Endogenous peroxidase was then inactivated by immersion in 0.3% H₂O₂ in phosphate buffer (phosphate-buffered saline 0.2 M, pH 7.0) for 30 min at room temperature. Normal goat serum diluted 1/30 in phosphate-buffered saline was then applied for 30 min at room temperature, followed by the primary antiserum. The primary antisera, all raised in rabbits, were applied at pre-determined optimal dilutions (see Table 1A) in phosphate-buffered saline for 16 h at 4° C in a damp chamber. For characterisation of antisera see Table 1A and B. After rinsing, the second layer antibody (goat anti-rabbit IgG, Miles, 1/100) was applied for 30 min at room temperature. Finally, after washing in phosphate-buffered saline, rabbit peroxidase anti-peroxidase (UCB) diluted 1/300 was placed on the sections. The specific sites of immunoreaction were developed in a solution of phosphate-buffered saline containing 0.0006% H₂O₂ and 0.025% diaminobenzidine (DAB) (Sigma St. Louis, MO, USA). The sections were then dehydrated through graded alcohols and xylene and mounted in a permanent medium (DPX).

Controls

The controls that were carried out comprised dilution of the primary antisera, their substitution with non-immune serum and their use after absorption with an excess of antigen against which they were thought to be specific. In view of the reported similarities among some of the antigens investigated (Bradshaw and Schneider 1980) the immunostaining was also verified using antisera preabsorbed with an excess of structurally related and unrelated antigens included in this study (Table 1B).

Results

A. Histological findings

Neuroblastic tumours. According to their histological appearance and signs of differentiation, cases were classified as follows: 3 cases as group A (undif-




Fig. 1. Undifferentiated neuroblastoma. Scattered immature neoplastic cells stained with anti-bodies to GFAP. Nomarski optics (mag. $\times 540$)




Fig. 2. Well-differentiated neuroblastoma. Mature ganglion cells with elongated cytoplasmic processes and a few neuroblasts stained using neuron specific enolase antibodies. Nomarski optics. Nuclear counterstain with diluted haematoxylin (mag. $\times 540$)

ferentiated), 15 cases as group B (poorly differentiated) and 12 cases as group C (well differentiated). Ganglion cells were detected in all cases from group C, while in group B they were observed in 7 cases out of 15.

Lymphomas. All 3 cases were classified as lymphoblastic lymphomas of diffuse pattern (Lennert 1978).

Ewing sarcomas. In these three cases small, uniform cells with scanty cytoplasm were observed. In two cases a rosette-like pattern was also detected.

B. Immunocytochemistry

All antibodies provided positive immunostaining. Suppression of the staining was obtained either using non-immune primary antisera or by preadsorption with their specific antigens but not by structurally related or unrelated ones (Table 1 B).

Undifferentiated neuroblastic tumours (group A). The 3 cases examined showed no positive immunoreactions for most of the antibodies tested.

Nevertheless, glial fibrillary acidic protein immunoreactivity was observed in one case. Scattered neoplastic cells were positively stained, although the majority of neuroblasts remained unreactive (Fig. 1).

No immunoreactivity for NSE, neurofilaments, S-100 or tyrosine hydroxylase was found in these 3 cases.

Poorly differentiated neuroblastic tumours (group B). Neuron-specific enolase and tyrosine hydroxylase were clearly demonstrated in the majority of mature ganglion cells and in numerous neuroblasts showing signs of differentiation such as increased cytoplasm and axon-like processes.

S-100 protein was often demonstrated in differentiating neuroblasts and in the tangled network of cell processes emanating from them (Fig. 4).

Positive staining for neurofilaments was observed in the perikarya of ganglion cells and in nerve bundles originating from them (Fig. 5). Neurofilaments were also detected in the cytoplasm of neuroblasts with large vesicular nuclei and in their cytoplasmic processes (Fig. 6) while immature neuroblasts were almost entirely unreactive.

Glial fibrillary acidic protein was found in some neoplastic cells with few or no signs of differentiation.

Well differentiated neuroblastic tumours. In this group of neoplasms NSE, tyrosine hydroxylase and neurofilaments were the antigens most frequently observed in the neoplastic cells.

NSE and tyrosine hydroxylase were detected in mature ganglion cells as well as in differentiating neuroblasts or "intermediate cells" (Figs. 2 and 3). Neurofilaments were localised in the perikarya of ganglion cell bodies and in their axons. Most of the differentiating neuroblasts were also positive.

S-100 protein was detected in the cytoplasm of differentiating neuro-




Fig. 3. Well-differentiated neuroblastoma. Numerous ganglion cells, often binucleate, showing strong immunoreactivity to tyrosine hydroxylase antibodies. Nomarski optics (mag. $\times 432$)




Fig. 4. Poorly differentiated neuroblastoma. A cluster of neuroblasts demonstrated using S-100 antibodies. Nomarski optics, nuclear counterstain with diluted haematoxylin (mag. $\times 675$)




Fig. 5. Poorly differentiated neuroblastoma. Numerous mature ganglion cells and maturing neuroblasts immunoreactive to antibodies to neurofilaments. Nomarski optics. Nuclear counterstain with diluted haematoxylin (mag. $\times 230$)



Fig. 6. Poorly differentiated neuroblastoma. Differentiated neuroblasts showing axon-like processes (*arrows*) positively stained using antibodies to neurofilaments. Nomarski optics (mag. $\times 540$)

blasts, while mature ganglion cells were negative. Glial fibrillary acidic protein was never found in this group of neoplasms.

Non-neuroblastic tumours. None of the neural antigens investigated was observed in the neoplastic cells of non-neuroblastic tumours (lymphomas and Ewing sarcomas), although positive staining for some of these antigens was sometimes found in non-neoplastic elements surrounded by the neoplastic growth. In fact, S-100 was localised in nerves and neurofilaments as well as NSE in nerves and ganglion cells.

Discussion

We have demonstrated the presence of neural antigens in 28 of 30 cases of neuroblastic tumours using a wide variety of antibodies.

Neuron-specific enolase was detected in partially differentiated and well differentiated tumours, localised in all mature ganglion cells as well as in differentiating neuroblasts. Its localisation in mature elements lends support to the hypothesis that the enzyme is not present in its specific form during the earlier stages of neuroblastic differentiation (Schmechel et al. 1980). NSE may therefore be considered as a reliable marker for partially differentiated neuroblastic tumours.

S-100 protein was found in neuroblasts with signs of maturation, particularly in poorly differentiated neuroblastic tumours. This observation suggests that S-100 may be present in neuroblasts during certain stages of maturation while progressively disappearing in more differentiated tumours. The occurrence of S-100 in the network of cytoplasmic processes arising from neuroblasts indicates that S-100 immunocytochemistry may be a useful tool for demonstrating these formations, so far difficult to stain with histochemical methods.

Neurofilaments were present in ganglion cells and maturing neuroblasts of more differentiated tumours. They were detected in cell bodies as well as in cytoplasmic processes.

These findings confirm the observation that at least some neuroblastomas may contain neurofilament immunoreactivity (Osborn and Weber 1983). Thus, neurofilaments could be another useful marker for neuroblastic neoplasms, particularly those undergoing initial differentiation.

The demonstration of NSE and NF in these cases supports the hypothesis that immature neoplastic cells tend to differentiate toward neuronal cell lines exhibiting two specific markers of neurons, both localised in the cytoplasm of the same cell types (maturing neuroblasts and ganglion cells).

Abnormal tangles of neurofilaments have been observed in some pathological non-neoplastic conditions (Dahl et al. 1982; Kluck et al. 1984). Further biochemical and ultrastructural analyses are needed to clarify the chemical composition and the spatial arrangement of neurofilament immunoreactivity in neuroblastoma cells.

In our study we have also observed the presence of glial antigens in neuroblastic tumours. Since S-100 as well as glial fibrillary acidic protein was shown in some neoplastic cells in cases with few or no parameters of maturation.

Evidence has been published suggesting that the GFAP molecule shares important similarities with neurofilaments (Goldman et al. 1978). The demonstration of GFAP immunoreactivity in some cases with no signs of maturation appears not to be due to cross reactivity with NF-like material, since preabsorption of GFAP antisera with a great excess of NF did not interfere with the immunostaining (see Table 1B). Moreover, NF immunoreactivity is present in those cases where GFAP immunoreactivity is virtually absent. These findings suggest that a minority of pluripotential precursor cells are present in most immature cases and that they may display, at least in these stages, specific glial markers such as GFAP.

Tyrosine hydroxylase has also been demonstrated in the majority of ganglion cells and in the so-called "intermediate cells" present in cases with signs of differentiation. Therefore our findings support the hypothesis that these tumours often contain adrenergic substances (Sunderman 1974) that are produced in ganglion cells. In every case each neural protein showed a specific pattern of distribution in a particular cellular element (neuroblast, ganglion cell, etc.). The predominant localisation of each neural protein depended on the degree of maturation of the tumour (Table 2A).

We conclude that a panel of antibodies to neuronal and glial markers may be extremely useful in the histological assessment of neuroblastic tumours and that comparison of the immunocytochemical pattern with the prognosis and the clinical stage of the disease is warranted.

Acknowledgements. Antibodies to tyrosine hydroxylase were kindly provided by Dr. J. Thibault. The authors are grateful to the Cancer Research Campaign for partly supporting this work.

References

- Bignami A, Eng FL, Dahl D, Uyeda CT (1972) Localization of the glial fibrillary acid protein in astrocytes by immunofluorescence. *Brain Res* 28:351–354
- Bradshaw RA, Schneider DM (1980) *Proteins of the nervous system*. 2nd Ed. Raven Press, New York
- Ceccamea A, Bonamico M, Napoleoni M (1981) Criteri istologici per la valutazione prognostica del neuroblastoma. *Tumori* 67:605–612
- Cocchia D, Michetti F (1981) S-100 antigen in satellite cells of the adrenal medulla and the superior cervical ganglion of the cat. An immunochemical and immunocytochemical study. *Cell Tissue Res* 215:103–112
- Cushing H, Wohlbach SB (1927) The transformation of a malignant paravertebral sympathicoblastoma into a benign ganglioneuroma. *Am J Pathol* 3:203–216
- Dahl D, Bignami A (1976) Immunogenic properties of the glial fibrillary acidic protein. *Brain Res* 116:150–157
- Dahl D, Bignami A (1977) Preparation of antisera to neurofilament protein from chicken brain and human sciatic nerve. *J Comp Neurol* 176:645–658
- Dahl D, Selkoe DJ, Pero RT, Bignami A (1982) Immunostaining of neurofibrillary tangles in Alzheimer's senile dementia with a neurofilament antiserum. *J Neurosci* 2:113–119
- Ferri GL, Probert, L, Cocchia D, Michetti F, Marangos PJ, Polak JM (1982) Evidence for the presence of S-100 protein in the glial component of the human enteric nervous system. *Nature* 297:409–410
- Fox F, Davidson J, Thomas LB (1959) Maturation of sympathicoblastoma into ganglioneuroma. Report of two patients with 20 and 46 year survivals respectively. *Cancer* 12:108–116
- Goldman JE, Schaumburg HH, Norton WT (1978) Isolation and characterisation of glial filaments from human brain. *J Cell Biol* 78:426–440

- Huang WM, Gibson SJ, Facer P, Gu J, Polak JM (1983) Improved section adhesion for immunocytochemistry using high molecular weight polymers of L-lysine as a slide coating. *Histochemistry* 77:275-279
- Hughes M, Marsden HB, Palmer MK (1974) Histologic patterns of neuroblastoma related to prognosis and clinical staging. *Cancer* 34:1706-1711
- Huneus FC, Davison PF (1970) Fibrillary proteins from squid axons. I. Neurofilament protein. *J Mol Biol* 52:415-428
- Jessen KR, Mirsky R (1980) Glial cells in the enteric nervous system contain glial fibrillary acidic protein. *Nature* 286:736-737
- Kahn HJ, Marks A, Thom H, Bauml R (1982) Role of antibody to S-100 protein in diagnostic pathology. *Am J Clin Pathol* 79 (3):341-347
- Kluck P, Van Muijen GNP, Van der Kamp WM, Tibboel D, Van Hoorn WA, Warnaar SO, Molenaar JC (1984) Hirschsprung's disease studied with monoclonal antineurofilament antibodies on tissue sections. *Lancet* I:652-653
- Lennert K (1978) Classification of non Hodgkin's Lymphomas. In: Lennert K. et al.: Malignant lymphomas other than Hodgkin disease. Histology, cytology, ultrastructure, immunology. Springer, Berlin Heidelberg New York pt. 3, pp 83-110
- Makinen J (1972) Microscopic patterns as a guide to prognosis of neuroblastoma in childhood. *Cancer* 29:1637-1646
- Marangos PJ, Zis AP, Clark RL, Goodwin FK (1978) Neuronal, non-neuronal and hybrid forms of enolase in brain: structural, immunological and functional comparisons. *Brain Res* 150:117-133
- Marangos PJ, Polak JM, Pearse AGE (1982) Neuron-specific enolase, a probe for peptide-secreting cells of the diffuse neuroendocrine system. In: Bloom SR, Polak JM, Lindenlaub E (eds) The systemic role of regulatory peptides. Symposium Oosterbeek Netherlands, May 2-6 1982. Symposia Medical Hoechst 18. FK Schattauer Verlag, Stuttgart New York
- Moore BW (1965) A soluble protein characteristic of the nervous system. *Biochem Biophys Res Commun* 19:739-744
- Nakajima T, Kameya T, Watanabe S, Hirota T, Sato Y, Shimosato Y (1982) An immunoperoxidase study of S-100 protein distribution in normal and neoplastic tissues. *Am J Surg Pathol* 6:715-727
- Osborn M, Weber K (1983) Tumor diagnosis by intermediate filament typing: a novel tool for surgical pathology. *Lab Invest* 48 (4):372-394
- Pearse AGE (1968) Common cytochemical and ultrastructural characteristics of cells producing polypeptide hormones (the APUD series) and their relevance to thyroid and ultimobranchial C-cells and calcitonin. *Proc Roy Soc (London)* 170:71
- Polak JM, Bloom SR (1979) The diffuse neuroendocrine system. *J Histochem Cytochem* 27:1938-1400
- Schlaepfer WW, Freeman L (1978) Neurofilament proteins of rat peripheral nerve and spinal cord. *J Cell Biol* 78:653-662
- Schmechel DE, Brightmann MW, Marangos PJ (1980) Neurons switch from non-neuronal enolase to neuron specific enolase during differentiation. *Brain Res* 190 (1):195-214
- Sternberger, LA (1979) Immunocytochemistry. 2nd Ed. Prentice-Hall, New Jersey
- Sunderman FW (1974) Measurement of Vanilmandelic acid for the diagnosis of phaeochromocytoma and neuroblastoma. *A J Clin Pathol* 42:481-497
- Tapia FJ, Polak JM, Barbosa AJA, Bloom SR, Marangos PJ, Dermody C, Pearse AGE (1981): Neuron specific enolase is produced by endocrine tumours. *Lancet* I, 808-811
- Thibault J, Vidal D, Gros F (1981) In vitro translation of mRNA from cat phaeochromocytoma tumours, characterisation of tyrosine hydroxylase. *Biochem Biophys Res Comm* 99 (3):960-968
- Wahl HR (1914) Neuroblastoma with study of a case illustrating the 3 types that arise from the sympathetic nervous system. *J Med Res* 30:205-260
- Zelter PM, Marangos PJ, Parma AM, Sather H, Dalton A, Hammon D, Siegel SF, Seeger RC (1983) Raised neuron specific enolase in serum of children in metastatic neuroblastoma. *Lancet* II:361-363